An important open question is whether HER2-low (IHC score 1+ or 2+/in situ hybridization [ISH]-negative) breast cancers should be considered as a separate subtype, especially after the emergence of novel antibody-drug conjugates (ADCs)38–40. This evidence concerns the gene ERBB2 and breast carcinoma.